Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

CK2 Pro-Survival Role in Prostate Cancer Is Mediated via Maintenance and Promotion of Androgen Receptor and NFκB p65 Expression.

Trembley JH, Kren BT, Abedin MJ, Shaughnessy DP, Li Y, Dehm SM, Ahmed K.

Pharmaceuticals (Basel). 2019 Jun 14;12(2). pii: E89. doi: 10.3390/ph12020089.

PMID:
31197122
2.

A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities.

Kounatidou E, Nakjang S, McCracken SRC, Dehm SM, Robson CN, Jones D, Gaughan L.

Nucleic Acids Res. 2019 Apr 22. pii: gkz286. doi: 10.1093/nar/gkz286. [Epub ahead of print]

PMID:
31006810
3.

Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.

Venkadakrishnan VB, DePriest AD, Kumari S, Senapati D, Ben-Salem S, Su Y, Mudduluru G, Hu Q, Cortes E, Pop E, Mohler JL, Azabdaftari G, Attwood K, Shah RB, Jamieson C, Dehm SM, Magi-Galluzzi C, Klein E, Sharifi N, Liu S, Heemers HV.

Oncogene. 2019 Jun;38(23):4496-4511. doi: 10.1038/s41388-019-0732-7. Epub 2019 Feb 11.

PMID:
30742064
4.

Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer.

Shapovalova M, Davydova J, Henzler C, Daniel M, Dehm SM, Warlick CA, LeBeau AM.

Oncotarget. 2018 Nov 30;9(94):36693-36704. doi: 10.18632/oncotarget.26401. eCollection 2018 Nov 30.

5.

AR-Variant-Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?

Dehm SM, Montgomery B, Plymate SR.

Clin Cancer Res. 2019 Mar 15;25(6):1696-1698. doi: 10.1158/1078-0432.CCR-18-3727. Epub 2018 Dec 27.

PMID:
30591516
6.

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.

Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, Syamala S, Bango C, Photopoulos C, Huang Y, Tyekucheva S, Bastos DC, Tchaicha J, Lawney B, Uo T, D'Anello L, Csibi A, Kalekar R, Larimer B, Ellis L, Butler LM, Morrissey C, McGovern K, Palombella VJ, Kutok JL, Mahmood U, Bosari S, Adams J, Peluso S, Dehm SM, Plymate SR, Loda M.

Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):631-640. doi: 10.1073/pnas.1808834116. Epub 2018 Dec 21.

7.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. No abstract available.

8.

A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.

Warren AY, Massie CE, Watt K, Luko K, Orafidiya F, Selth LA, Mohammed H, Chohan BS, Menon S, Baridi A, Zhao W, Escriu C, Pungsrinont T, D'Santos C, Yang X, Taylor C, Qureshi A, Zecchini VR, Shaw GL, Dehm SM, Mills IG, Carroll JS, Tilley WD, McEwan IJ, Baniahmad A, Neal DE, Asim M.

Oncogene. 2019 Feb;38(7):1136-1150. doi: 10.1038/s41388-018-0501-z. Epub 2018 Sep 20.

PMID:
30237440
9.

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Yang R, Henzler C, Li Y, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, Goad J, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Dehm SM, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA, Risbridger GP.

Eur Urol. 2018 Nov;74(5):562-572. doi: 10.1016/j.eururo.2018.06.020. Epub 2018 Jul 23.

PMID:
30049486
10.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19. Erratum in: Cell. 2018 Oct 18;175(3):889.

11.

Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.

Li D, Tian G, Wang J, Zhao LY, Co O, Underill ZC, Mymryk JS, Claessens F, Dehm SM, Daaka Y, Liao D.

Prostate. 2018 Nov;78(15):1140-1156. doi: 10.1002/pros.23689. Epub 2018 Jul 15.

PMID:
30009471
12.

Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing.

Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, Haradhvala NJ, Freeman SS, Reed SC, Rhoades J, Polak P, Cipicchio M, Wankowicz SA, Wong A, Kamath T, Zhang Z, Gydush GJ, Rotem D; PCF/SU2C International Prostate Cancer Dream Team, Love JC, Getz G, Gabriel S, Zhang CZ, Dehm SM, Nelson PS, Van Allen EM, Choudhury AD, Adalsteinsson VA, Beroukhim R, Taplin ME, Meyerson M.

Cell. 2018 Jul 12;174(2):433-447.e19. doi: 10.1016/j.cell.2018.05.036. Epub 2018 Jun 18.

PMID:
29909985
13.

Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients.

Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):411-418. doi: 10.1038/s41391-018-0043-z. Epub 2018 Jun 1.

14.

Indel detection from DNA and RNA sequencing data with transIndel.

Yang R, Van Etten JL, Dehm SM.

BMC Genomics. 2018 Apr 19;19(1):270. doi: 10.1186/s12864-018-4671-4.

15.

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.

Eur Urol. 2018 May;73(5):715-723. doi: 10.1016/j.eururo.2017.11.038. Epub 2017 Dec 16. Review.

16.

A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone.

Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M.

Ann Oncol. 2018 Feb 1;29(2):352-360. doi: 10.1093/annonc/mdx689.

17.

Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate Cancer.

Van Etten JL, Nyquist M, Li Y, Yang R, Ho Y, Johnson R, Ondigi O, Voytas DF, Henzler C, Dehm SM.

Cancer Res. 2017 Oct 1;77(19):5228-5235. doi: 10.1158/0008-5472.CAN-17-0320. Epub 2017 Aug 15.

18.

Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.

Dalal K, Che M, Que NS, Sharma A, Yang R, Lallous N, Borgmann H, Ozistanbullu D, Tse R, Ban F, Li H, Tam KJ, Roshan-Moniri M, LeBlanc E, Gleave ME, Gewirth DT, Dehm SM, Cherkasov A, Rennie PS.

Mol Cancer Ther. 2017 Oct;16(10):2281-2291. doi: 10.1158/1535-7163.MCT-17-0259. Epub 2017 Aug 3.

19.

Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation.

Yin Y, Li R, Xu K, Ding S, Li J, Baek G, Ramanand SG, Ding S, Liu Z, Gao Y, Kanchwala MS, Li X, Hutchinson R, Liu X, Woldu SL, Xing C, Desai NB, Feng FY, Burma S, de Bono JS, Dehm SM, Mani RS, Chen BPC, Raj GV.

Cancer Res. 2017 Sep 15;77(18):4745-4754. doi: 10.1158/0008-5472.CAN-17-0164. Epub 2017 Jul 28.

20.

Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.

Kohli M, Ho Y, Hillman DW, Van Etten JL, Henzler C, Yang R, Sperger JM, Li Y, Tseng E, Hon T, Clark T, Tan W, Carlson RE, Wang L, Sicotte H, Thai H, Jimenez R, Huang H, Vedell PT, Eckloff BW, Quevedo JF, Pitot HC, Costello BA, Jen J, Wieben ED, Silverstein KAT, Lang JM, Wang L, Dehm SM.

Clin Cancer Res. 2017 Aug 15;23(16):4704-4715. doi: 10.1158/1078-0432.CCR-17-0017. Epub 2017 May 4.

21.

Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer.

Paltoglou S, Das R, Townley SL, Hickey TE, Tarulli GA, Coutinho I, Fernandes R, Hanson AR, Denis I, Carroll JS, Dehm SM, Raj GV, Plymate SR, Tilley WD, Selth LA.

Cancer Res. 2017 Jul 1;77(13):3417-3430. doi: 10.1158/0008-5472.CAN-16-1616. Epub 2017 May 4.

22.

Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.

Ho Y, Dehm SM.

Endocrinology. 2017 Jun 1;158(6):1533-1542. doi: 10.1210/en.2017-00109. Review.

23.

Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.

Isharwal S, Modi S, Arora N, Uhlrich C 3rd, Giri B, Barlass U, Soubra A, Chugh R, Dehm SM, Dudeja V, Saluja A, Banerjee S, Konety B.

Prostate. 2017 May;77(6):584-596. doi: 10.1002/pros.23298. Epub 2017 Feb 1.

24.

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.

Henzler C, Li Y, Yang R, McBride T, Ho Y, Sprenger C, Liu G, Coleman I, Lakely B, Li R, Ma S, Landman SR, Kumar V, Hwang TH, Raj GV, Higano CS, Morrissey C, Nelson PS, Plymate SR, Dehm SM.

Nat Commun. 2016 Nov 29;7:13668. doi: 10.1038/ncomms13668.

25.

CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors.

Ahmed K, Kren BT, Abedin MJ, Vogel RI, Shaughnessy DP, Nacusi L, Korman VL, Li Y, Dehm SM, Zimmerman CL, Niehans GA, Unger GM, Trembley JH.

Oncotarget. 2016 Sep 20;7(38):61789-61805. doi: 10.18632/oncotarget.11442.

26.

Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation.

Sperger JM, Strotman LN, Welsh A, Casavant BP, Chalmers Z, Horn S, Heninger E, Thiede SM, Tokar J, Gibbs BK, Guckenberger DJ, Carmichael L, Dehm SM, Stephens PJ, Beebe DJ, Berry SM, Lang JM.

Clin Cancer Res. 2017 Feb;23(3):746-756. doi: 10.1158/1078-0432.CCR-16-1021. Epub 2016 Jul 11.

27.

Methods for Identifying and Quantifying mRNA Expression of Androgen Receptor Splicing Variants in Prostate Cancer.

Li Y, Dehm SM.

Methods Mol Biol. 2016;1443:165-77. doi: 10.1007/978-1-4939-3724-0_11.

PMID:
27246340
28.

Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.

Antonarakis ES, Armstrong AJ, Dehm SM, Luo J.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):231-41. doi: 10.1038/pcan.2016.17. Epub 2016 May 17. Review.

29.

Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer.

Daniel M, Dehm SM.

J Steroid Biochem Mol Biol. 2017 Feb;166:28-37. doi: 10.1016/j.jsbmb.2016.04.016. Epub 2016 Apr 28. Review.

30.

Clonal origin and spread of metastatic prostate cancer.

Van Etten JL, Dehm SM.

Endocr Relat Cancer. 2016 Apr;23(4):R207-17. doi: 10.1530/ERC-16-0049. Epub 2016 Mar 21. Review.

31.

Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy.

Kohli M, Wang L, Xie F, Sicotte H, Yin P, Dehm SM, Hart SN, Vedell PT, Barman P, Qin R, Mahoney DW, Carlson RE, Eckel-Passow JE, Atwell TD, Eiken PW, McMenomy BP, Wieben ED, Jha G, Jimenez RE, Weinshilboum R, Wang L.

PLoS One. 2015 Dec 22;10(12):e0145176. doi: 10.1371/journal.pone.0145176. eCollection 2015.

32.

Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.

Asim M, Massie CE, Orafidiya F, Pértega-Gomes N, Warren AY, Esmaeili M, Selth LA, Zecchini HI, Luko K, Qureshi A, Baridi A, Menon S, Madhu B, Escriu C, Lyons S, Vowler SL, Zecchini VR, Shaw G, Hessenkemper W, Russell R, Mohammed H, Stefanos N, Lynch AG, Grigorenko E, D'Santos C, Taylor C, Lamb A, Sriranjan R, Yang J, Stark R, Dehm SM, Rennie PS, Carroll JS, Griffiths JR, Tavaré S, Mills IG, McEwan IJ, Baniahmad A, Tilley WD, Neal DE.

J Natl Cancer Inst. 2015 Dec 11;108(5). doi: 10.1093/jnci/djv371. Print 2016 May.

33.

Expression of androgen receptor splice variants in clinical breast cancers.

Hickey TE, Irvine CM, Dvinge H, Tarulli GA, Hanson AR, Ryan NK, Pickering MA, Birrell SN, Hu DG, Mackenzie PI, Russell R, Caldas C, Raj GV, Dehm SM, Plymate SR, Bradley RK, Tilley WD, Selth LA.

Oncotarget. 2015 Dec 29;6(42):44728-44. doi: 10.18632/oncotarget.6296.

34.

Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.

Chan SC, Selth LA, Li Y, Nyquist MD, Miao L, Bradner JE, Raj GV, Tilley WD, Dehm SM.

Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.

35.

EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer.

Brand LJ, Olson ME, Ravindranathan P, Guo H, Kempema AM, Andrews TE, Chen X, Raj GV, Harki DA, Dehm SM.

Oncotarget. 2015 Feb 28;6(6):3811-24.

36.

Constitutive activity of the androgen receptor.

Chan SC, Dehm SM.

Adv Pharmacol. 2014;70:327-66. doi: 10.1016/B978-0-12-417197-8.00011-0. Review.

37.

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.

Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM.

Endocr Relat Cancer. 2014 Aug;21(4):T87-T103. doi: 10.1530/ERC-13-0470. Epub 2014 May 23. Review.

38.

SHEAR: sample heterogeneity estimation and assembly by reference.

Landman SR, Hwang TH, Silverstein KA, Li Y, Dehm SM, Steinbach M, Kumar V.

BMC Genomics. 2014 Jan 29;15:84. doi: 10.1186/1471-2164-15-84.

39.

TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.

Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, Voytas DF, Dehm SM.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17492-7. doi: 10.1073/pnas.1308587110. Epub 2013 Oct 7.

40.

Test-firing ammunition for spliceosome inhibition in cancer.

Dehm SM.

Clin Cancer Res. 2013 Nov 15;19(22):6064-6. doi: 10.1158/1078-0432.CCR-13-2461. Epub 2013 Oct 4.

41.

mRNA splicing variants: exploiting modularity to outwit cancer therapy.

Dehm SM.

Cancer Res. 2013 Sep 1;73(17):5309-14. doi: 10.1158/0008-5472.CAN-13-0444. Epub 2013 Aug 22. Review.

42.

Androgen receptor gene rearrangements: new perspectives on prostate cancer progression.

Brand LJ, Dehm SM.

Curr Drug Targets. 2013 Apr;14(4):441-9. Review.

43.

FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.

Bohrer LR, Liu P, Zhong J, Pan Y, Angstman J, Brand LJ, Dehm SM, Huang H.

Prostate. 2013 Jul;73(10):1017-27. doi: 10.1002/pros.22649. Epub 2013 Feb 6.

44.

Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression.

Nyquist MD, Dehm SM.

Horm Cancer. 2013 Apr;4(2):61-9. doi: 10.1007/s12672-013-0131-4. Epub 2013 Jan 10. Review.

45.

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM.

Cancer Res. 2013 Jan 15;73(2):483-9. doi: 10.1158/0008-5472.CAN-12-3630. Epub 2012 Nov 1.

46.

Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer.

Kohli M, Qin R, Jimenez R, Dehm SM.

Adv Urol. 2012;2012:781459. doi: 10.1155/2012/781459. Epub 2012 Aug 22.

47.
48.

AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression.

Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, Hirsch B, Beckman KB, Silverstein KA, Dehm SM.

Oncogene. 2012 Nov 8;31(45):4759-67. doi: 10.1038/onc.2011.637. Epub 2012 Jan 23.

49.

Alternatively spliced androgen receptor variants.

Dehm SM, Tindall DJ.

Endocr Relat Cancer. 2011 Sep 20;18(5):R183-96. doi: 10.1530/ERC-11-0141. Print 2011 Oct. Review.

50.

Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.

Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM.

Cancer Res. 2011 Mar 15;71(6):2108-17. doi: 10.1158/0008-5472.CAN-10-1998. Epub 2011 Jan 19.

Supplemental Content

Support Center